https://doi.org/10.4081/mw.2026.40
The efficacy and safety of psilocybin-assisted therapy for major depressive disorder: a meta-analytic review of clinical outcomes
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Accepted: 23 March 2026
Published: 21 April 2026
This systematic review and meta-analysis synthesized data from 13 clinical trials (n=606) evaluating psilocybin-assisted psychotherapy for major depressive disorder and treatment-resistant depression. Despite early enthusiasm, the pooled standardized mean difference (-0.79, 95% confidence interval: -3.98 to 2.40, p=0.63) revealed no statistically significant overall antidepressant effect, with extreme heterogeneity (I2=96.9%) across studies. Notably, the type of control group (active comparator vs. placebo/waitlist) accounted for 98.7% of between-study variance, with waitlist and low-dose comparators producing exaggerated effect sizes. Session frequency was a significant moderator: 2 to 5 psilocybin sessions yielded larger effects, while more intensive protocols attenuated benefit. Neither participant age nor follow-up duration significantly influenced outcomes. Evidence of reporting bias and small-study effects was detected (Egger’s test p=0.012). Sensitivity analyses demonstrated that no single study accounted for the non-significant pooled result. Overall, psilocybin’s antidepressant efficacy appears highly context-dependent—shaped by trial design, comparator, and session structure—rather than universally robust. These findings underscore the need for larger, rigorously controlled trials to clarify psilocybin’s therapeutic role in depression.
Downloads
World Health Organization. Depression. 2021. Available from: https://www.who.int/news-room/fact-sheets/detail/depression
Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006;163:1905-17. DOI: https://doi.org/10.1176/ajp.2006.163.11.1905
Carhart-Harris RL, Goodwin GM. The therapeutic potential of psychedelic drugs: past, present, and future. Neuropsychopharmacology 2017;42:2105-13. DOI: https://doi.org/10.1038/npp.2017.84
Johnson MW, Garcia-Romeu A, Cosimano MP, Griffiths RR. Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. J Psychopharmacol 2014;28:983-92. DOI: https://doi.org/10.1177/0269881114548296
Griffiths RR, Johnson MW, Carducci MA, et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. J Psychopharmacol 2016;30:1181-97. DOI: https://doi.org/10.1177/0269881116675513
Ross S, Bossis A, Guss J, et al. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial. J Psychopharmacol 2016;30:1165-80. DOI: https://doi.org/10.1177/0269881116675512
Carhart-Harris RL, Erritzoe D, Williams T, et al. Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. Proc Natl Acad Sci U S A 2012;109:2138-43. DOI: https://doi.org/10.1073/pnas.1119598109
Vollenweider FX, Preller KH. Psychedelic drugs: neurobiology and potential for treatment of psychiatric disorders. Nat Rev Neurosci 2020;21:611-24. DOI: https://doi.org/10.1038/s41583-020-0367-2
Davis AK, Barrett FS, May DG, et al. Effects of psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial. JAMA Psychiatry 2020;78:1-9. DOI: https://doi.org/10.1001/jamapsychiatry.2020.3285
Gukasyan N, Davis AK, Barrett FS, et al. Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: prospective 12-month follow-up. J Psychopharmacol 2022;36:151-8. DOI: https://doi.org/10.1177/02698811211073759
Carhart-Harris R, Giribaldi B, Watts R, et al. Trial of psilocybin versus escitalopram for depression. N Engl J Med 2021;384:1402-11. DOI: https://doi.org/10.1056/NEJMoa2032994
Reiff CM, Richman EE, Nemeroff CB, et al. Psychedelics and psychedelic-assisted psychotherapy. Am J Psychiatry 2020;177:391-410. DOI: https://doi.org/10.1176/appi.ajp.2019.19010035
Rucker JJH, Iliff J, Nutt DJ. Psychiatry and the psychedelic drugs: past, present, and future. Neuropharmacology 2018;142:200-18. DOI: https://doi.org/10.1016/j.neuropharm.2017.12.040
Johnson MW, Garcia-Romeu A, Griffiths RR. Long-term follow-up of psilocybin-facilitated smoking cessation. Am J Drug Alcohol Abuse 2017;43:55-60. DOI: https://doi.org/10.3109/00952990.2016.1170135
Studerus E, Gamma A, Kometer M, Vollenweider FX. Prediction of psilocybin response in healthy volunteers. PLoS One 2012;7:e30800. DOI: https://doi.org/10.1371/journal.pone.0030800
Yao Y, Guo D, Lu TS, et al. Efficacy and safety of psychedelics for the treatment of mental disorders: a systematic review and meta-analysis. Psychiatry Res 2024;335:115886. DOI: https://doi.org/10.1016/j.psychres.2024.115886
Asebey EJ, O’Reilly JT. FDA law and the psychedelic renaissance. FDLI Update. 2024. Available from: https://heinonline.org/HOL/LandingPage?handle=hein.journals/fdliup2024&div=8&id=&page=
Agrawal M, Richards W, Beaussant Y, et al. Psilocybin‐assisted group therapy in patients with cancer diagnosed with a major depressive disorder. Cancer 2024;130:1137-46. DOI: https://doi.org/10.1002/cncr.35010
Goodwin GM, Croal M, Feifel D, et al. Psilocybin for treatment resistant depression in patients taking a concomitant SSRI medication. Neuropsychopharmacology 2023;48:1492-9. DOI: https://doi.org/10.1038/s41386-023-01648-7
von Rotz R, Schindowski EM, Jungwirth J, et al. Single-dose psilocybin-assisted therapy in major depressive disorder: a placebo-controlled, double-blind, randomised clinical trial. EClinicalMedicine 2022;56:101809. DOI: https://doi.org/10.1016/j.eclinm.2022.101809
Henry J, Giribaldi B, Nutt DJ, et al. The effects of psilocybin therapy versus escitalopram on cognitive bias: a secondary analysis of a randomized controlled trial. medRxiv 2025;2025-03. DOI: https://doi.org/10.1101/2025.03.17.25324123
Raison CL, Sanacora G, Woolley J, et al. Single-dose psilocybin treatment for major depressive disorder: a randomized clinical trial. JAMA 2023;330:843-53. DOI: https://doi.org/10.1001/jama.2023.14530
Back AL, Freeman-Young TK, Morgan L, et al. Psilocybin therapy for clinicians with symptoms of depression from frontline care during the COVID-19 pandemic: a randomized clinical trial. JAMA Netw Open 2024;7:e2449026. DOI: https://doi.org/10.1001/jamanetworkopen.2024.49026
Barba T, Buehler S, Kettner H, et al. Effects of psilocybin versus escitalopram on rumination and thought suppression in depression. BJPsych Open 2022;8:e163. DOI: https://doi.org/10.1192/bjo.2022.565
Erritzoe D, Barba T, Spriggs MJ, et al. Effects of discontinuation of serotonergic antidepressants prior to psilocybin therapy versus escitalopram for major depression. J Psychopharmacol 2024;38:458-70. DOI: https://doi.org/10.1177/02698811241237870
Rosenblat JD, Meshkat S, Doyle Z, et al. Psilocybin-assisted psychotherapy for treatment resistant depression: a randomized clinical trial evaluating repeated doses of psilocybin. Med 2024;5:190-200. DOI: https://doi.org/10.1016/j.medj.2024.01.005
Goodwin GM, Aaronson ST, Alvarez O, et al. Single-dose psilocybin for a treatment-resistant episode of major depression: impact on patient-reported depression severity, anxiety, function, and quality of life. J Affect Disord 2023;327:120-7. DOI: https://doi.org/10.1016/j.jad.2023.01.108
Haikazian S, Chen-Li DCJ, Johnson DE, et al. Psilocybin-assisted therapy for depression: a systematic review and meta-analysis. Psychiatry Res 2023;329:115531. DOI: https://doi.org/10.1016/j.psychres.2023.115531
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
